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BSTRACT
 
Background
 
The thalassemias are common in
southern China. We determined the prevalence of
heterozygous carriers of these genetic disorders in
Hong Kong and assessed the feasibility of a commu-
nity-based screening program.
 
Methods
 
An educational and screening program
for the thalassemias was carried out in three high
schools with a total of 2420 students. Seventy-five
percent of the students agreed to undergo screen-
ing, which consisted of blood counts, hemoglobin
electrophoresis, serum ferritin measurements, and
DNA analyses.
 
Results
 
Of the 1800 blood samples tested, 150
(8.3 percent) had microcytosis (mean corpuscular
volume, 
 

 
80 
 
m
 
m
 
3
 
). Ninety students (5.0 percent)
were carriers of 
 
a
 
-thalassemia, of whom 81 (4.5 per-
cent) were carriers of the Southeast Asian type of
deletion, in which both 
 
a
 
-globin genes on the same
chromosome 16 are deleted. Sixty-one students (3.4
percent) were carriers of either 
 
b
 
-thalassemia or the
mutation coding for hemoglobin E. Six students
were carriers of both 
 
a
 
- and 
 
b
 
-thalassemias. On the
basis of these figures, the estimated numbers of
pregnancies in Hong Kong in which the fetus is at
risk for homozygous 
 
a
 
-thalassemia and 
 
b
 
-thalasse-
mia major or intermedia are 145 and 80 per year, re-
spectively. In Hong Kong the actual numbers of
women referred for prenatal diagnoses of these dis-
orders are approximately 95 and 40 per year, respec-
tively.
 
Conclusions
 
Despite the availability of hospital-
based screening and prenatal diagnosis for many
years in Hong Kong, many women carrying fetuses
at risk for thalassemia are not referred for genetic
counseling. A community-based program of educa-
tion, screening, and counseling is needed in Hong
Kong and southern China. (N Engl J Med 1997;336:
1298-301.)
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HE 
 
a
 
- and 
 
b
 
-thalassemias are due to mu-
tations of the 
 
a
 
- or 
 
b
 
-globin genes that
markedly decrease or completely prevent
the production of 
 
a
 
- or 
 
b
 
-globin chains.
 
1
 
They are the most common inherited single-gene
disorders in the world, with the highest prevalence in
areas where malaria has been or remains endemic. In
Southeast Asia, with a population of approximately
450 million people, the burdens of inherited globin
gene disorders in many regions are of such magni-
tude that they represent a public health concern.
 
2
 
We assessed the feasibility of a large screening pro-
gram for thalassemia in Hong Kong, a city of 6 mil-
lion people, and determined the thalassemia-carrier
rates. The results indicate that given the proper in-
formation, most high-school students, as well as their
parents and teachers, are receptive to a screening
program for thalassemia. The data confirm that ap-
proximately 8 percent of the population in Hong
Kong are heterozygous carriers of 
 
a
 
- or 
 
b
 
-thalasse-
mia mutations.
 
METHODS
 
Subjects
 
Students from three high schools in separate middle-class or
working-class neighborhoods (Hong Kong West, Kowloon City,
and Shek Kip Mei) were chosen for this study. In these three
schools, there were 2420 students in grades 9 to 13, ranging from
14 to 19 years of age. Ninety-eight percent of these students were
ethnic southern Chinese. One of us discussed the study with the
three school principals and obtained their approval and coopera-
tion in this investigation.
Educational sessions on the thalassemias given by a pediatrician
or a trained nurse were held in school auditoriums for all the stu-
dents and the teaching staff. Afterward, each student was given
an information sheet and a consent form for his or her parents to
sign. At a later scheduled session, 5 ml of venous blood, which
was anticoagulated with EDTA, was obtained from each partici-
pant with a signed parental consent form. Although the study was
designed primarily for the students, 72 teachers also asked to be
tested.
Each participant received a written report of the results of the
screening tests. Those who were found to be carriers of thalasse-
mia mutations were given an opportunity to receive additional in-
formation and counseling, initially with a trained nurse. If deemed
necessary, counseling with a pediatrician was arranged. Twenty-
two students attended these counseling sessions. In addition, all
carriers received a card printed with their thalassemia-carrier sta-
tus for their records and future reference.
 
Hematologic Studies
 
Peripheral-blood counts and red-cell indexes were determined
according to standard laboratory procedures with the use of
Technicon H*1 and H*2 blood analyzers (Technicon, Tarrytown,
N.Y.). Hemoglobin H inclusion bodies were detected by incubat-
ing peripheral blood with brilliant cresyl blue for 30 minutes at
Copyright © 1997 Massachusetts Medical Society. All rights reserved. 
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37°C.
 
3
 
 Cellulose acetate electrophoresis was used to analyze he-
moglobins at a pH of 8.5. Hemoglobin A
 
2
 
 and fetal hemoglobin
were quantitated by the variant hemoglobin testing system (Bio-
Rad Laboratories, Hercules, Calif.). We used an immunocytolog-
ic technique to detect embryonic 
 
z
 
-globin chains with a murine
monoclonal antibody against 
 
z
 
-globin chains as previously de-
scribed.
 
3,4
 
 Serum ferritin levels were measured with the IMx Fer-
ritin Assay kit (Abbott Laboratories, Abbott Park, Ill.).
 
Molecular Analyses
 
DNA was extracted from peripheral-blood leukocytes. The
 
a
 
-globin genotypes were determined by Southern blotting, hy-
bridized with probes specific for 
 
a
 
- and 
 
z
 
-globin genes, as well as
the 3
 

 
 hypervariable region probe as indicated.
 
5
 
 To search for the
hemoglobin Constant Spring variant (
 
a
 
CS
 
), which results in the
elongation of the 
 
a
 
-globin chain, the 
 
a
 
2-globin gene was ampli-
fied by the polymerase chain reaction (PCR) and subjected to dot
blotting for hybridization with allele-specific–oligonucleotide
nonradioactive probes. PCR was also used to identify the South-
east Asian type of deletion (--
 
SEA
 
), in which both 
 
a
 
-globin genes
on the same chromosome 16 are deleted.
 
6
 
Mutations in the 
 
b
 
-globin gene were identified by PCR-based
diagnostic strategies, including one using heteroduplexes to de-
tect the deletion of CTTT in codons 41 and 42, dot blotting
with allele-specific–oligonucleotide nonradioactive probes to iden-
tify the substitution of thymine for cytosine at position 654 in
IVS2 as well as the mutation in the 
 
b
 
E
 
 allele, and direct nucleotide
sequencing to detect all other mutations.
 
5
 
 The deletion causing
(
 
A
 
gdb
 
)
 
0
 
-thalassemia was detected by Southern blotting with a
probe specific for the 
 
G
 
g
 
-globin gene.
 
7
 
RESULTS
 
Of the 2420 students who attended the informa-
tional meetings, 1812 (75 percent) obtained paren-
tal consent and agreed to undergo screening. A total
of 1800 blood samples were obtained and analyzed
(12 students were absent from school on the days on
which phlebotomy was scheduled).
One hundred fifty of the 1800 blood samples (8.3
percent) had microcytosis (mean corpuscular volume
of less than 80 
 
m
 
m
 
3
 
). These 150 blood samples were
tested for 
 
a
 
- and 
 
b
 
-thalassemias and iron deficiency.
The 
 
a
 
-globin genotypes of all 150 blood samples
were determined both by Southern analysis and by
PCR with primers specific for the (--
 
SEA
 
) type of
 
a
 
-thalassemia deletion. Mutations in the 
 
b
 
-globin
gene clusters were determined only in blood samples
with hemoglobin A
 
2
 
 concentrations above 3.5 percent.
Mutations related to 
 
a
 
-thalassemia were found in
90 of the 1800 samples screened, or 5.0 percent
(Table 1). More important, 81 blood samples (4.5
percent) had the (--
 
SEA
 
) deletion. One sample had a
deletion of the complete 
 
z
 
–
 
a
 
-globin gene cluster.
Three cases of hemoglobin H disease, involving the
deletion of three 
 
a
 
-globin genes, were identified.
Triplicated 
 
a
 
-globin genes were found in five sam-
ples. The 
 
a
 
CS
 
 mutation was not found in any sample.
Sixty-one of the 1800 blood samples screened (3.4
percent) had 
 
b
 
-thalassemia mutations, including that
coding for hemoglobin E (Table 1). Two thirds of
these mutations were accounted for by the deletion
of CTTT in codons 41 and 42 and by the substitu-
tion of thymine for cytosine at position 654 in IVS2,
in agreement with previous studies.
 
8-10
 
 Six persons
were carriers of both 
 
a
 
- and 
 
b
 
-thalassemia mutations.
One carrier of probable hemoglobin Queens was
identified by hemoglobin electrophoresis.
Five students had iron deficiency, with serum fer-
ritin levels of less than 10 
 
m
 
g per liter.
 
DISCUSSION
 
Approximately 2400 high school students attend-
ed the educational sessions on the thalassemias, and
75 percent voluntarily entered the screening pro-
gram by obtaining parental consent and undergoing
phlebotomy. This high level of receptivity by stu-
dents and their families in a properly designed
screening program for thalassemia carriers is nota-
ble. Recently, Mitchell et al. reported the result of a
long-term (begun in 1980) screening program for
carriers of thalassemia among high-school students
in Montreal.
 
11
 
 They found a high rate of voluntary
participation in the programs, a high rate of use of
reproductive-counseling options later in life, and a
major decline in the incidence of 
 
b
 
-thalassemia ma-
jor in the province of Quebec.
 
11
 
Thalassemias are common in southern China.
 
12-14
 
In the population we screened, 4.6 percent (95 per-
cent confidence interval, 3.6 to 5.6 percent) were
 
*Six subjects were carriers of both 
 
a
 
- and 
 
b
 
-thalassemia mutations, three
had hemoglobin H disease with deletion of three 
 
a
 
-globin genes, and five
were carriers of triplicated 
 
a
 
-globin genes.
 
T
 
ABLE
 
 1.
 
 R
 
ESULTS
 
 OF SCREENING OF BLOOD SAMPLES
FROM 1800 HIGH-SCHOOL STUDENTS FOR MICROCYTOSIS,
THALASSEMIA-CARRIER STATUS, AND IRON DEFICIENCY.
VARIABLE
NO. OF 
BLOOD
SAMPLES
(N1800) PERCENT
Microcytosis (mean corpuscular volume, 
80 mm3)
150 8.3
Deletion associated with a-thalassemia*
(--SEA) Deletion
Deletion of the complete z–a-globin gene
cluster
(-a3.7) Deletion
(-a4.2) Deletion
Undetermined
90
81
1
6
3
2
5.0
4.5
0.06
0.3
0.2
0.1
Mutation coding for b-thalassemia*
Deletion of CTTT at codons 41–42
C→T at position 654 in IVS2
A→G at nucleotide 28
A→T at codon 17
G→T at codon 43
Insertion of A at codons 71–72
Deletion causing (Agdb)0-thalassemia
55
22
18
8
3
2
1
1
3.1
1.2
1.0
0.4
0.2
0.1
0.06
0.06
Mutation coding for mutant hemoglobin
Glu→Lys at codon 26 in the b-globin chain
(hemoglobin E)
Probable Leu→Arg at codon 34 in the a-globin 
chain (hemoglobin Queens)
7
6
1
0.4
0.3
0.06
Iron deficiency 5 0.3
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heterozygous carriers of a-thalassemia involving ei-
ther the (--SEA) deletion or a deletion of the com-
plete z–a-globin gene cluster (Tables 1 and 2) and
were therefore at risk of conceiving fetuses with he-
moglobin Bart’s hydrops fetalis syndrome (absence
of all four a-globin genes; commonly, (--SEA/--SEA).
This study confirms that immunocytologic staining
for embryonic z-globin chains in peripheral-blood
smears is a reliable way to identify adult carriers of
the (--SEA) deletion (data not shown).3-5 We found
a low prevalence of deletions involving a single
a-globin gene (0.5 percent), but it is likely that
many carriers of such mutations have mean corpus-
cular volumes of more than 80 mm3 and therefore
escaped detection in our screening program.16,17
Fetuses with hemoglobin Bart’s hydrops fetalis
syndrome usually die in utero during the third tri-
mester or shortly after birth. Serious developmental
anomalies, including severe retardation of brain
growth, have been reported in these fetuses.1,18 More-
over, their mothers have an increased risk of serious
complications during pregnancy.18 In Hong Kong,
where there are approximately 70,000 births a year,
the number of pregnancies involving a fetus at risk
for hemoglobin Bart’s hydrops fetalis syndrome
would be about 145 per year (95 percent confidence
interval, 93 to 221) (Table 3).
Carriers of b-thalassemia mutations including that
coding for hemoglobin E accounted for 3.4 percent
(95 percent confidence interval, 2.6 to 4.3 percent)
of the population screened (Tables 1 and 2). They
are at risk of having children with b-thalassemia ma-
jor and, less frequently, thalassemia intermedia. In
addition, a small number of persons are found to be
carriers of both a- and b-thalassemia mutations. In
the past, children with b-thalassemia major often did
not survive to adolescence in developing countries
because of the lack of proper health care. This bleak
outlook has changed because of the marked eco-
nomic progress and improved health care in many
countries of the Pacific Rim. In Hong Kong, all chil-
dren with b-thalassemia major currently receive reg-
ular blood transfusions and iron-chelation therapy
with deferoxamine.19,20 With optimal medical care
and patient compliance, these children are expected
to live to be at least 30 years old.21-24 Thirty children
with b-thalassemia major in Hong Kong have un-
dergone hematopoietic stem-cell transplantation.25
*The 95 percent confidence intervals (CI) were computed according to
the method of Gardner et al.15 
TABLE 2. PREVALENCE OF CLINICALLY SIGNIFICANT 
a- AND b-THALASSEMIA MUTATIONS.
VARIABLE
NO. OF
SAMPLES
(N1800)
PREVALENCE 
(95% CI)*
percent
Microcytosis (mean corpuscular volume, 
80 mm3)
150 8.3 (7.1–9.7)
a- or b-Thalassemia mutations 145 8.1 (6.8–9.4)
(--SEA) Deletion or deletion of the complete 
z–a-globin gene cluster
82 4.6 (3.6–5.6)
b-Thalassemia or hemoglobin E mutations 61 3.4 (2.6–4.3)
*The projected numbers were calculated from the values in Table 2, as follows: for a-thalassemia,
70,000 births per year  (821800)2; and for b-thalassemia, 70,000  (611800).2 The 95 percent
confidence intervals (CI) were calculated from data in Table 2.
†Data are from the Prenatal Diagnostic and Counselling Department, Tsan Yuk Hospital, Hong Kong.
‡The fetuses either had hemoglobin Bart’s hydrops fetalis syndrome or were homozygous or com-
pound heterozygous for b-thalassemia. All couples with affected pregnancies requested termination
of the pregnancies.
§The fetuses were normal or were heterozygous for a- or b-thalassemia.
TABLE 3. PRENATAL DIAGNOSIS OF PREGNANCIES ASSOCIATED WITH A RISK OF 
a- AND b-THALASSEMIA IN HONG KONG.
YEAR
PROJECTED NO.
OF PREGNANCIES
AT RISK
(95% CI)*
ACTUAL NO.
OF PREGNANCIES WITH
REFERRAL FOR PRENATAL
DIAGNOSIS†
NO. OF
AFFECTED
FETUSES‡
NO. OF 
UNAFFECTED
FETUSES§
a-Thalassemia
1993 145 (93–221) 94 19 75
1994 145 (93–221) 96 28 68
1995 145 (93–221) 95 22 73
b-Thalassemia
1993 80 (48–131) 45 10 35
1994 80 (48–131) 28 5 23
1995 80 (48–131) 46 6 40
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Despite this progress, b-thalassemia major remains a
serious physical, emotional, and financial burden for
patients and their families.26 The related health care
costs are very high. For example, the annual cost of
blood transfusions and deferoxamine treatment for
one patient with b-thalassemia major has been re-
ported to be $30,000 (in U.S. currency).26 On the
basis of our results, we estimate that there are 80
pregnancies (95 percent confidence interval, 48 to
131) per year in Hong Kong in which the fetus is at
risk for b-thalassemia major or intermedia (Table 3).
During the past three years in Hong Kong, ap-
proximately 95 women have been referred annually
for prenatal diagnosis of a-thalassemia, and approx-
imately 40 for b-thalassemia (Table 3). These figures
suggest that many women in Hong Kong whose
pregnancies are at risk of resulting in children with
either homozygous a-thalassemia or b-thalassemia
major are not identified and referred for genetic
counseling. At least 287 patients with transfusion-
dependent b-thalassemia major are currently attend-
ing pediatric clinics in the eight government-funded
hospitals in Hong Kong19; 110 of these patients are
under the age of 10.19
The success in Sardinia, Italy, and elsewhere in re-
ducing the prevalence of thalassemia major by genet-
ic counseling shows that screening can have a major
impact in communities in which the thalassemias are
common.27,28 Our study demonstrates the feasibility
and potential benefits of a community-based screen-
ing program in Hong Kong and in the three neigh-
boring provinces of southern China, where 130 mil-
lion people are at risk for these disorders.
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